CVA 21

Drug Profile

CVA 21

Alternative Names: Cavatak; Coxsackievirus A21; CVA21

Latest Information Update: 06 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroTarg
  • Developer Merck & Co; Olivia Newton-John Cancer Research Institute; Viralytics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action CD55 antigen inhibitors; Cell death stimulants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Bladder cancer; Lung cancer; Non-small cell lung cancer; Prostate cancer; Uveal melanoma
  • Suspended Head and neck cancer
  • No development reported Breast cancer; Chronic lymphocytic leukaemia; Glioma; Mesothelioma; Multiple myeloma; Pancreatic cancer

Most Recent Events

  • 06 Feb 2018 Phase-I clinical trials in Uveal melanoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03408587)
  • 22 Nov 2017 Phase-I development is underway in Bladder-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom and USA, in Lung-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom, USA, in Bladder-cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in United Kingdom, in Lung-cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in United Kingdom, in Malignant-melanoma (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in United Kingdom, in Prostate-cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in United Kingdom (IV, Infusion) (NCT02043665)
  • 13 Nov 2017 Viralytics plans the phase Ib CLEVER trial in Uveal melanoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top